LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

Search

Vivani Medical

Open

1.2 0.84

Overview

Share price change

24h

Current

Min

1.18

Max

1.21

Key metrics

By Trading Economics

Income

-103K

-6.6M

Employees

42

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+209.92% upside

Dividends

By Dow Jones

Next Earnings

11 May 2026

Market Stats

By TradingEconomics

Market Cap

19M

92M

Previous open

0.36

Previous close

1.2

Vivani Medical Chart

Past performance is not a reliable indicator of future results.

Related News

7 May 2026, 23:58 UTC

Earnings

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 May 2026, 22:57 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 May 2026, 23:52 UTC

Earnings

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 May 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 May 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 May 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 May 2026, 23:11 UTC

Earnings

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 May 2026, 23:06 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 May 2026, 23:05 UTC

Earnings

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 May 2026, 23:04 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 May 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 May 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 May 2026, 23:02 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 May 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 May 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 May 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 May 2026, 22:42 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 May 2026, 22:33 UTC

Earnings
Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 May 2026, 22:32 UTC

Earnings

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 May 2026, 22:31 UTC

Earnings

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 May 2026, 22:31 UTC

Earnings

Macquarie: 68% of FY Income From International >MQG.AU

7 May 2026, 22:30 UTC

Earnings

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 May 2026, 22:30 UTC

Earnings

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 May 2026, 22:29 UTC

Earnings

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 May 2026, 22:28 UTC

Earnings

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 May 2026, 22:28 UTC

Earnings

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 May 2026, 22:27 UTC

Earnings

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 May 2026, 22:27 UTC

Earnings

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 May 2026, 22:26 UTC

Earnings

Macquarie to End Share Buyback Extended in November>MQG.AU

7 May 2026, 22:25 UTC

Earnings

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Comparison

Price change

Vivani Medical Forecast

Price Target

By TipRanks

209.92% upside

12 Months Forecast

Average 3.75 USD  209.92%

High 4 USD

Low 3.5 USD

Based on 2 Wall Street analysts offering 12 month price targets forVivani Medical - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Pre-tax profit

Sales

Operating profit

$

About Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
help-icon Live chat